Altfest L J & Co. Inc. purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,094 shares of the medical equipment provider’s stock, valued at approximately $654,000.
Several other institutional investors have also modified their holdings of ZBH. Kentucky Retirement Systems acquired a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at $1,500,000. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at $669,000. Chevy Chase Trust Holdings Inc. boosted its position in shares of Zimmer Biomet Holdings by 3.7% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 175,789 shares of the medical equipment provider’s stock valued at $21,466,000 after buying an additional 6,217 shares in the last quarter. Curbstone Financial Management Corp acquired a new position in shares of Zimmer Biomet Holdings during the first quarter valued at $218,000. Finally, CENTRAL TRUST Co boosted its position in shares of Zimmer Biomet Holdings by 13.0% in the first quarter. CENTRAL TRUST Co now owns 5,055 shares of the medical equipment provider’s stock valued at $617,000 after buying an additional 580 shares in the last quarter. 83.62% of the stock is owned by institutional investors.
Zimmer Biomet Holdings, Inc. (ZBH) traded down 1.83% during midday trading on Tuesday, hitting $115.04. The stock had a trading volume of 1,551,015 shares. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The company has a 50-day moving average price of $126.96 and a 200-day moving average price of $121.31. The stock has a market cap of $23.22 billion, a P/E ratio of 32.77 and a beta of 1.20.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.95 billion. During the same period in the prior year, the company earned $2.02 EPS. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.
ILLEGAL ACTIVITY NOTICE: “Altfest L J & Co. Inc. Acquires New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/09/altfest-l-j-co-inc-invests-654000-in-zimmer-biomet-holdings-inc-nysezbh-updated.html.
Several equities analysts have recently weighed in on ZBH shares. Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Thursday, April 13th. Wells Fargo & Company cut shares of Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research note on Friday, April 28th. Needham & Company LLC raised their price target on shares of Zimmer Biomet Holdings from $151.00 to $153.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Friday, April 28th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research note on Friday, April 28th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $137.76.
In related news, insider Sang Yi sold 17,731 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Tony W. Collins sold 16,986 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is owned by corporate insiders.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
